- Home
- GITS vs ASBP Comparison
GITS vs ASBP Comparison
Compare GITS & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GITS | ASBP |
|---|---|---|
| Founded | 2018 | 2021 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 7.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GITS | ASBP |
|---|---|---|
| Price | $2.64 | $0.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 110.3K | ★ 161.0K |
| Earning Date | 11-12-2025 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.05 |
| 52 Week High | $7.09 | $2.45 |
Technical Indicators
Market Signals| Indicator | GITS | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 32.39 |
| Support Level | $2.13 | $0.12 |
| Resistance Level | $3.03 | $0.88 |
| Average True Range (ATR) | 0.37 | 0.14 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 56.96 | 16.98 |
Price Performance
Historical ComparisonAbout GITS Global Interactive Technologies Inc.
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.